BC
Broadfin Capital Portfolio holdings
AUM
$403M
This Quarter Return
-9.91%
1 Year Return
+74.97%
3 Year Return
+245.63%
5 Year Return
+336.04%
10 Year Return
–
AUM
$485M
AUM Growth
+$485M
(-13%)
Cap. Flow
+$58.2M
Cap. Flow
% of AUM
11.99%
Top 10 Holdings %
Top 10 Hldgs %
53.68%
Holding
58
New
11
Increased
13
Reduced
15
Closed
9
Top Buys
| 1 |
NVRO
NEVRO CORP.
NVRO
|
$29M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
$25.1M |
| 3 |
DexCom
DXCM
|
$18.7M |
| 4 |
Aclaris Therapeutics
ACRS
|
$13.9M |
| 5 |
Incyte
INCY
|
$11.7M |
Top Sells
| 1 |
CORI
Corium International, Inc.
CORI
|
$22.5M |
| 2 |
Tandem Diabetes Care
TNDM
|
$18.4M |
| 3 |
Pacific Biosciences
PACB
|
$13.5M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$11.8M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$8.04M |
Sector Composition
| 1 | Healthcare | 87.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Iovance Biotherapeutics
IOVA
$807M
| $52.7M | 6.93% | 5,951,153 +1,056,792 | +22% | +$9.35M |
|
|
TSRO
2
DELISTED
TESARO, Inc.
TSRO
| $32.8M | 4.32% | 442,219 +337,519 | +322% | +$25.1M |
|
|
NVRO
3
DELISTED
NEVRO CORP.
NVRO
| $29M | 3.81% | +744,415 | New | +$29M |
|
|
PETX
4
DELISTED
Aratana Therapeutics, Inc.
PETX
| $25M | 3.29% | 4,083,135 | – | – |
|
5
Travere Therapeutics
TVTX
$1.56B
| $23M | 3.02% | 1,016,114 +77,900 | +8% | +$1.76M |
|
|
ADMS
6
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $22.3M | 2.94% | 2,614,468 +1,286,044 | +97% | +$11M |
|
|
7
DexCom
DXCM
$29.5B
| $21.6M | 2.83% | 179,900 +155,700 | +643% | +$18.7M |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $19.5M | 2.57% | 535,998 -121,900 | -19% | -$4.44M |
|
|
LJPC
9
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $18.4M | 2.41% | 1,947,541 -106,450 | -5% | -$1M |
|
|
BDSI
10
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $16.2M | 2.13% | 4,375,066 | – | – |
|
|
SCTL
11
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $14.5M | 1.91% | 2,048,025 | – | – |
|
|
12
Aclaris Therapeutics
ACRS
$209M
| $13.9M | 1.82% | +1,877,502 | New | +$13.9M |
|
|
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
| $12.6M | 1.66% | 2,821,722 +258,626 | +10% | +$1.16M |
|
14
Catalyst Pharmaceutical
CPRX
$2.52B
| $12M | 1.58% | 6,268,298 +1,132,034 | +22% | +$2.17M |
|
|
15
Incyte
INCY
$16.5B
| $11.7M | 1.53% | +183,300 | New | +$11.7M |
|
|
NSTG
16
DELISTED
NanoString Technologies, Inc.
NSTG
| $10.7M | 1.41% | 720,600 -129,400 | -15% | -$1.92M |
|
|
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $10.4M | 1.37% | 1,697,582 +892,882 | +111% | +$5.46M |
|
18
ADMA Biologics
ADMA
$4.12B
| $10.1M | 1.33% | 4,226,077 -237,752 | -5% | -$568K |
|
|
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.89M | 1.3% | +240,909 | New | +$9.89M |
|
|
ATRS
20
DELISTED
Antares Pharma, Inc.
ATRS
| $9.37M | 1.23% | 3,444,147 -1,179,100 | -26% | -$3.21M |
|
21
Integra LifeSciences
IART
$1.18B
| $8.87M | 1.17% | 196,572 | – | – |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.48M | 1.12% | 200,000 -157,672 | -44% | -$6.69M |
|
|
XENT
23
DELISTED
Intersect ENT, Inc
XENT
| $8.11M | 1.07% | 287,900 +53,700 | +23% | +$1.51M |
|
|
AVDL
24
Avadel Pharmaceuticals
AVDL
$1.43B
| $8.01M | 1.05% | 3,102,673 +309,900 | +11% | +$800K |
|
|
SRRA
25
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $6.44M | 0.85% | 4,880,327 +789,983 | +19% | +$1.04M |
|